权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

University of California and UT Southwestern D-PDTC

加州大学和 UT 西南 D-PDTC

基本信息

批准号：
10733391
负责人：
Luis Guillermo Carvajal Carmona
金额：
$ 106.11万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-01 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10733391
关键词：
Advanced Malignant Neoplasm Affect Asian Asian ancestry Asian population Bioinformatics Biological Biological Process California Cancer Biology Cancer Center Cancer Model Cancer Therapy Evaluation Program Catchment Area Cause of Death Cell Cycle Cells Clinical Clinical Trials Collection Combination Drug Therapy Combined Modality Therapy Complex Comprehensive Cancer Center Data Decision Making Development Digit structure Disease Disparity Drug Combinations Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor FDA approved FRAP1 gene Family Female Frequencies Genetic Genome Genomics Goals Grant Health Disparities Research Implant Indigenous American Infrastructure Latina Population Latino Latino Population Light Los Angeles Lung Neoplasms Malignant Neoplasms Malignant neoplasm of lung Minority Minority Groups Modeling Molecular Molecular Abnormality Mutate Mutation Oncogenes PI3K/AKT Pathway interactions Patient Isolation Patients Pharmaceutical Preparations Phosphotransferases Pilot Projects Population Population Heterogeneity Pre-Clinical Model Precision Health Precision therapeutics Preclinical Drug Development Preclinical Testing Process Productivity Publishing Regimen Research Research Personnel Research Project Grants Resistance Resources Risk Factors Role San Francisco Signal Transduction Site Smoking Smoking History Solid Stomach Stomach Neoplasms Testing Texas Time Translating Underrepresented Minority Universities Woman Work cancer diagnosis cancer health disparity cancer subtypes comparative effective therapy ethnic diversity ethnic minority expectation health equity malignant stomach neoplasm member minority patient molecular subtypes mortality mortality disparity multidisciplinary mutant never smoker new therapeutic target novel patient derived xenograft model people of color precision oncology racial diversity racial minority resistance mechanism response response biomarker targeted cancer therapy targeted treatment therapeutically effective treatment response tumor tumor diagnosis tumorigenesis

项目摘要

PROJECT SUMMARY/ABSTRACT The University of California and the University of Texas Southwestern (UCaTS) Diversity Patient-Derived Xenograft (PDX) Development and Trial Center’s is a diversity-focused grant with a goal of establishing and characterizing at least 120 new PDXs from racially and ethnically diverse populations and use these PDXs as preclinical models to better understand the mechanisms of oncogenesis, to test FDA-approved and NCI-CTEP single agent and drug combination therapies and to advance cancer health disparities research. Expanding the existing PDX infrastructure from our ongoing University of California Patient Derived and Trial Center (UCaMP, U54CA233306), UCaTS is comprised of six NCI-designated Comprehensive Cancer Centers (CCC): UC Davis Comprehensive Cancer Center (UCD) [lead institution], UC Irvine Chao Family Comprehensive Cancer Center (UCI), UC Los Angeles Jonsson Comprehensive Cancer Center (UCLA), UC San Diego Moores Cancer Center (UCSD), UC San Francisco Helen Diller Family Comprehensive Cancer Center (UCSF), and the University of Texas Southwestern Harold C. Simmons Cancer Center (UTSW). Collectively, UCaTS includes a team of transdisciplinary investigators with strengths in PDX development, preclinical drug testing, cancer health disparities, clinical trial development, bioinformatics, and large multicenter administration. UCaTS will achieve its goal through two Research Projects. Project 1 – “Advancing gastric cancer precision medicine in Latinos through patient-derived modeling” focuses on developing novel, effective therapeutic regimens for most commonly druggable and genomically complex Latino GC subtype, which involves co-mutations in multiple pathway (such as cell cycle kinase, PI3K/AKT/mTOR, WNT and RTK-RAS) and to study resistance mechanisms to targeted therapies, identify response biomarkers and assess how ancestry influences response. Project 2 – “Precision targeting of disparity-associated EGFR mutant lung tumors to circumvent early resistance to EGFR inhibitors”, focuses on one of the most common lung cancer (LC) subtypes in minority populations, EGFR- mutated lung tumors. This molecular subtype represents a high proportion of lung cancer diagnosed in female patients of Latino and Asian ancestry. The project will utilize PDXNet and our UCaTS lung cancer PDX expertise and resources to develop effective targeted therapy combinations with FDA-approved and NCI-CTEP agents seeking to overcome early resistance to EGFR-TKIs.

项目总结/文摘